Journal of Evaluation in Clinical Practice · 2019 · 19 citations · 24 references
PharmacyCommunity PharmacyPharmacy PracticeClinical PharmacologyGeriatric AssessmentGeriatric PharmacotherapyHigh-risk Medication ReviewMedication Adherence In Older AdultsMedication ReviewMedication UseComprehensive Geriatric Medication ReviewGeriatric Medication AssessmentMedication Review AssessmentObservational Study AnalysisPharmacist-led Medication ReviewPolypharmacy Screening ToolsPotentially Inappropriate Medication Review
Abstract Rationale, aims, and objectives The Ghent Older People's Prescriptions community Pharmacy Screening (GheOP 3 S)‐tool was recently developed as an explicit screening tool to detect drug‐related problems (DRPs) and to help in performing medication reviews. In this study, we aimed (a) to describe the characteristics of the detected DRPs and the subsequent pharmacists' recommendations with their acceptance and implementation rate resulting from a pharmacist‐led medication review using the GheOP 3 S‐tool and (b) to assess the potential impact of the intervention. Method Prospective observational study in community‐dwelling older patients (70 years or older, using five or more medications). Community pharmacists performed medication reviews resulting in the documentation of “GheOP 3 S‐related DRPs” and “other DRPs” with corresponding pharmacists' recommendations. Acceptance was recorded during face‐to‐face pharmacist‐general practitioner (GP) meetings. Implementation was assessed after a 3‐month follow‐up by consulting the electronic pharmacy record, the patient, and/or GP. The potential impact on the number of medications, the number of “GheOP 3 S‐related DRPs”, the anticholinergic and sedative burden quantified by the Drug Burden Index (DBI), and medication costs was assessed by a pre‐post comparison of the patients' medication lists. Results Twenty‐one pharmacists detected 470 DRPs with a median (IQR) of 6 (4‐8) per patient in 75 patients (about half “GheOP 3 S‐related DRPs” and half “other DRPs”). Most prevalent recommendations were stopping (22.9%) and substituting (18.9%) medication. Overall acceptance was 66.9%. At follow‐up, 42.9% of all recommendations were implemented. The number of GheOP 3 S‐criteria ( P < .001) and the DBI scores ( P = .033) significantly differed from baseline. This was not the case for the number of chronic medications and medication costs. Conclusions This study demonstrates a relatively high acceptance of pharmacists' recommendations, although implementation could be improved. Pharmacist‐led medication reviews with multidisciplinary meetings using the GheOP 3 S‐tool can have a potential impact on the number of DRPs and the anticholinergic and sedative burden of patients.
24
Erik von Elm, Douglas G. Altman, Matthias Egger et al. · The Lancet · 2007 · 18.7K citations · Full text
Public Health, Public Health Practice, Epidemiologic Methods +10
Erik von Elm, Douglas G. Altman, Matthias Egger et al. · Annals of Internal Medicine · 2007 · 17.2K citations
Public Health, Public Health Practice, Epidemiologic Methods +10
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Felicia Cosman, Suzanne M. Jan de Beur, Meryl S. LeBoff et al. · Osteoporosis International · 2014 · 4.1K citations · Full text
Danijela Gnjidic, Sarah N. Hilmer, Fiona Blyth et al. · Journal of Clinical Epidemiology · 2012 · 1.2K citations